Microbiologic and Clinical Implications of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae with or without Plasmid-Mediated AmpC β-Lactamase DHA-1-Reference-Cited by-同舟云学术

Microbiologic and Clinical Implications of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae with or without Plasmid-Mediated AmpC β-Lactamase DHA-1

Published:2010-12 Issue:12 Volume:54 Page:5395-5398
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lee Chen-Hsiang¹²,Su Lin-Hui³⁴,Li Chia-Chin⁵,Chien Chun-Chih⁵,Tang Ya-Fen²⁵,Liu Jien-Wei¹²

Affiliation:

1. Division of Infectious Diseases, Department of Internal Medicine

2. Nosocomial Infection Control Team

3. Department of Clinical Pathology, Chang Gung Memorial Hospital, Lin Kou Medical Center, Taiwan

4. Department of Medical Biotechnology and Laboratory Science, Chang Gung University College of Medicine, Taiwan

5. Department of Clinical Pathology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan

Abstract

ABSTRACT Bacteremias caused by Klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL-KP; n = 52) and producing both ESBL and AmpC-type DHA-1 beta-lactamase (ESBL-PMABL-KP; n = 20) were analyzed. Higher MIC 50 s and MIC 90 s for carbapenems, ciprofloxacin, and piperacillin-tazobactam were observed with ESBL-PMABL-KP than with ESBL-KP. Patients with oxyimino-β-lactam exposure and high modified Pitt bacteremia scores (HMPBSs) were at higher risk, while those with piperacillin-tazobactam and aminoglycoside exposure were at lower risk for ESBL-KP bacteremia. Patients with fluoroquinolone exposure, diabetes mellitus, and HMPBS were at higher risk, while those with aminoglycoside exposure were at lower risk, for ESBL-PMABL-KP bacteremia.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00083-10

Reference20 articles.

1. Performance standards for antimicrobial susceptibility testing 2009

2. Performance standards for antimicrobial susceptibility testing 2010

3. Goering, R. V. 2004. Pulsed-field gel electrophoresis, p. 185-196. In D. H. Persing, F. C. Tenover, J. Versalovic, Y. W. Tang, E. R. Unger, D. A. Relman and T. H. White (ed.), Molecular microbiology: diagnostic principles and practice. ASM Press, Washington, DC.

4. Grimm, H. 1991. Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef. Infection19(Suppl. 5):258-263.

5. AmpC β-Lactamases

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AmpC β-lactamase among Enterobacteriaceae: A new insight;Gene Reports;2020-06

2. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options;Expert Review of Anti-infective Therapy;2019-11-20

3. In vitro activity of flomoxef against extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumoniae in Korea;Diagnostic Microbiology and Infectious Disease;2019-05

4. Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study;Journal of Microbiology, Immunology and Infection;2018-10

5. An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate;Journal of Clinical Microbiology;2018-01